Bristol-Myers Squibb Company (BMY) Launches $300M Immunology Spinout with Bain Capital

We recently compiled a list of the 10 High Growth Pharma Stocks That Are Profitable in 2025. Bristol-Myers Squibb Company stands eighth among them.

Bristol-Myers Squibb Company (NYSE:BMY), a global biopharma leader, is making bold moves to strengthen its immunology presence through strategic partnerships and a growing pipeline. In July 2025, the company announced a joint venture with Bain Capital to launch an independent immunology-focused firm, backed by $300 million in financing. The new company will advance five assets, including a late-stage lupus therapy and a mid-stage psoriasis treatment, both showing encouraging results.

Under the agreement, Bristol-Myers Squibb Company (NYSE:BMY) will retain a 20% equity stake and receive milestone payments and royalties tied to future success. The move allows the corporation to leverage external expertise and capital while freeing internal resources to pursue next-generation drug development. Industry veterans will lead the new spinout, ensuring strong scientific and operational direction, positioning the company among high growth stocks in the biopharma sector.

This expansion complements Bristol-Myers Squibb Company (NYSE:BMY)’s broader mission of advancing therapies across oncology, cardiology, fibrosis, and immunology. With more than 48 compounds in active development across 40+ disease areas, the company is investing heavily in cutting-edge research platforms, including protein degradation and antibody-drug conjugates.

While we acknowledge the potential of BMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure. None.